Skip to main content
. 2017 May;9(5):1295–1302. doi: 10.21037/jtd.2017.03.167

Figure 2.

Figure 2

Progression free survival curves by all patients or each clinicopathological factors. (A) Progression free survival of pulmonary pleomorphic carcinoma (n=24); (B) progression free survival of pulmonary pleomorphic carcinoma divided by the tissue type of epithelial component (P=0.00846); (C) progression free survival of pulmonary pleomorphic carcinoma divided by the vascular invasion (P=0.0256); (D) progression free survival of pulmonary pleomorphic carcinoma divided by the lymph node metastasis (P=0.0138).